Liposomal Vincristine

DRUG3 trials

Sponsors

M.D. Anderson Cancer Center, Universität des Saarlandes, St. Jude Children's Research Hospital

Conditions

Acute Lymphoblastic LeukemiaCD20+ Aggressive B-Cell LymphomaLeukemiaLeukemia, B-CellLeukemia, T-CellLymphomaLymphoma, Non-Hodgkin'sOsteosarcoma

Phase 2

Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies

CompletedNCT00038207

M.D. Anderson Cancer CenterLeukemia, Lymphoma, Osteosarcoma +2

Start: 2000-06-30End: 2005-09-30Updated: 2018-10-31

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

TerminatedNCT02518750

St. Jude Children's Research HospitalAcute Lymphoblastic Leukemia, Leukemia, B-Cell, Leukemia, T-Cell +1

Start: 2016-11-23End: 2018-03-11Updated: 2019-04-03

Phase 3

OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

CompletedNCT01478542

Universität des SaarlandesCD20+ Aggressive B-Cell Lymphoma

Start: 2011-11-30End: 2024-01-18Updated: 2025-01-08

Related Papers

Impact of PRF 1 A91V germline carrier status in patients with aggressive b-NHL treated with rituximab

Blood2025-11-03

PET/CT imaging of pancreatic carcinoma targeting the “cancer integrin” αvβ6

European Journal of Nuclear Medicine and Molecular Imaging2021-06-0923 citations

FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.

2021-04-2923 citations

Fast-Track Schedule for Vitamin D3 Substitution in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Blood2020-11-04

Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL.

Journal of Clinical Oncology2017-05-2036 citations

Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy.

Journal of Clinical Oncology2017-05-204 citations